Medical Hypotheses
Volume 59, Issue 4 , Pages 378-384 , October 2002

The possible role of prolactin in preeclampsia: 2001, a hypothesis revisited a quarter of century later

  • A Parra

      Affiliations

    • Corresponding Author InformationCorrespondence to: Adalberto Parra, MD, Instituto Nacional de Perinatologia, Montes Urales 800, Lomas Virreyes, 11000 México, D.F., Mexico. Fax: +11-52-202-9861
    • ,
  • J Ramı́rez-Peredo

Received 16 July 2001 ,Accepted 2 November 2001.

References 

  1. Horrobin DF. The possible role of prolactin in preeclampsia. Med. Hypotheses. 1975;1:159–164
  2. Yuen BH, Cannon W, Wooley S, Charles E. Maternal plasma and amniotic fluid prolactin levels in normal and hypertensive pregnancy. Br. J. Obstet. Gynaecol. 1978;85:293–298
  3. Ranta T, Stenman UH, Unnerus HA, Rossi J, Seppala M. Maternal plasma prolactin levels in preeclampsia. Obstet. Gynecol. 1980;55:428–430
  4. Luciano AA, Varner MW. Decidual, amniotic fluid, maternal and fetal prolactin in normal and abnormal pregnancies. Obstet. Gynecol. 1984;63:384–388
  5. Golander A, Kopel R, Lazebnik N, Frenkel Y, Spirer Z. Decreased prolactin secretion by decidual tissue of preeclampsia in vitro. Acta Endocrinol. (Copenhagen). 1985;108:111–113
  6. McCoshen JA, Tyson JE. Altered prolactin bioactivity in amniotic fluid of hypertensive pregnancy. Obstet. Gynecol. 1985;65:24–30
  7. Miyakawa I, Taniyama K, Sakata M, Yamaguchi M, Mori N. Prolactin in severe toxemia of pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 1986;23:25–30
  8. Perloff D. Hypertension and pregnancy-related hypertension. Cardiol. Clin. 1998;16:79–101
  9. Nesss RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am. J. Obstet. Gynecol. 1996;175:1365–1370
  10. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J. Clin. Invest. 1973;52:2682–2689
  11. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am. J. Obstet. Gynecol. 1998;179:1359–1375
  12. Roberts JM, Cooper DW. Pathogenesis and genetics of preeclampsia. Lancet. 2001;357:53–56
  13. Satter N, Gaw A, Packard CJ, Greer IA. Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in preeclampsia. Br. J. Obstet. Gynaecol. 1996;103:614–620
  14. Hwang P, Guyda H, Friesen H. A radioimmunoassay for human prolactin. Proc. Natl. Acad. Sci. USA. 1971;68:1902–1906
  15. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 1998;19:225–268
  16. Bern HA, Nicoll CA. The comparative endocrinology of prolactin. Rec. Prog. Horm. Res. 1968;24:681–720
  17. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function and regulation of secretion. Physiol. Rev. 2000;80:1523–1631
  18. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions and clinical aspects. Endocr. Rev. 1996;17:639–669
  19. Debieve F, Beerlandt S, Hubinont C, Thomas K. Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fetal serum from midpregnancy and term pregnancy. J. Clin. Endocrinol. Metab. 2000;85:270–274
  20. Tadokoro N, Koibuchi N, Ohtake H, et al.  Localization of prolactin and its receptor messenger RNA in the human decidua. Experientia. 1995;51:1216–1219
  21. Wu WX, Brooks J, Glasier AF, McNeilly AS. The relationship between decidualization and prolactin mRNA and production at different stages of human pregnancy. J. Mol. Endocrinol. 1995;14:255–261
  22. Kanda Y, Jikihara H, Markoff E, Handwerger S. Interleukin-2 inhibits the synthesis and release of prolactin from human decidual cells. J. Clin. Endocrinol. Metab. 1999;84:677–681
  23. Lavalle C, Loyo E, Paniagua R, et al.  Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J. Rheumatol. 1987;14:268–272
  24. Besedovsky HO, del Rey A. Immune neuro-endocrine interactions: facts and hypothesis. Endocr. Rev. 1996;17:64–102
  25. Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin. Immunol. Immunopathol. 1993;66:201–211
  26. Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology. 1996;137:5456–5462
  27. Parra A, Ramírez-Peredo J, Larrea F, et al.  Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin. Endocrinol. (Oxford). 2001;54:731–738
  28. Parra A, Ramı́rez-Peredo J, Larrea F, et al.  Serum prolactin is associated with apoptosis in men with human immunodeficiency virus infection. Immunol. Cell Biol. 2001;79:285–290
  29. Matera L, Cesano A, Muccioli G, Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int. J. Neurosci. 1990;51:265–267
  30. Sinha YN. Prolactin variants. Trends Endocrinol. Metab. 1992;2:100–106
  31. Montgomery DW, Shen GK, Ulrich ED, Steiner LL, Parrish PR, Zukoski CF. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology. 1992;131:3019–3026
  32. Fukuoka H, Hamamoto R, Higurashi M. Heterogeneity of serum and amniotic fluid prolactin in humans. Horm. Res. 1991;35(suppl. 1):58–63
  33. Larrea F, Martı́nez-Castillo A, Cabrera V, et al.  A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and non stimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J. Clin. Endocrinol. Metab. 1997;82:3664–3669
  34. Clapp C, Martial JA, Guzmán RC, Rentier-Delure F, Weiner RI. The 16-kDa N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993;133:1292–1299
  35. Clapp C, Weiner RI. A specific high affinity saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology. 1992;130:1380–1386
  36. Struman I, Bentzien F, Lee H, et al.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA. 1999;96:1246–1251
  37. Clapp C, López-Gómez FJ, Nava G, et al.  Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. J. Endocrinol. 1998;158:137–144
  38. Bonissou P, Brisson GR, Peronnet F, Helie R, Ledoux M. Inhibition of exercise-induced blood prolactin response by acute hypoxia. Can. J. Sport Sci. 1987;12:49–50
  39. Struder HK, Hollmann W, Donike M, Platen P, Weber K. Effects of O2 availability on neuroendocrine variables at rest and during exercise: O2 breathing increases plasma prolactin. Eur. J. Appl. Physiol. Occup. Physiol. 1996;74:443–449
  40. Gordon JD, Shifren JL, Foulk RA, Taylor RN, Jaffe RB. Angiogenesis in the human female reproductive tract. Obstet. Gynecol. Surv. 1995;50:688–697
  41. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of preeclampsia. Placenta. 2000;21(suppl. A):S25–30
  42. Formby B. Immunologic response in pregnancy. Endocrinol. Metab. Clin. N. Am. 1995;24:187–205
  43. Carmeliet P, Dor Y, Herbert JM, et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 1998;394:485–490
  44. Clevenger ChV, Sillman AL, Hanley-Hyde J, Prystowsky MB. Requiremenet for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 1992;130:3216–3222
  45. Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am. J. Obstet. Gynecol. 2001;184:1249–1250
  46. Singh HJ, Rahman A, Larmie ET, Nila A. Endothelin-1 in feto-placental tissues from normotensive pregnant women and women with preeclampsia. Acta Obstet. Gynecol. Scand. 2001;80:99–103
  47. Chao HS, Myres SE, Handwerger S. Endothelin inhibits basal and stimulated release of prolactin by human decidual cell. Endocrinology. 1993;133:505–510
  48. Hamai Y, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Pathogenic implications of interleukin-2 expressed in preeclamptic decidual tissues: A possible mechanism of deranged vasculature of the placenta associated with preeclampsia. Am. J. Reprod. Immunol. 1997;38:83–88
  49. Corbacho AM, Nava G, Eiserich JP, et al.  Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. J. Biol. Chem. 2000;275:13183–13186
  50. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285:1607–1612
  51. Zhang X, Danila DC, Katai M, Swearingen B, Klibanski A. Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas. J. Clin. Endocrinol. Metab. 1999;84:4652–4655

PII: S0306-9877(02)00124-X

Medical Hypotheses
Volume 59, Issue 4 , Pages 378-384 , October 2002

Article Tools

* Image Usage & Resolution